Robert O. Kerr M.D.
Dr. Robert Kerr has been involved in laboratory and clinical research for more than twenty-five years and has been invited to present the results of his research in both the United States and Europe. He is the author of numerous publications and has served as president of the Texas Division of the American Cancer Society, president of the Texas Society of Medical Oncology, and chief of medical staff at two hospitals in Austin, TX. Additionally he has served as chairman and member of several state and national committees. Dr. Kerr is a regular presenter of Oncology CME. He is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the European Society of Medical Oncology. He is board certified in Internal Medicine and Hematology. More recently, Dr. Kerr has served on the review board of 2 IRBs reviewing over 150 investigative plans. Prior to dedicating his time to support pharmaceutical IND applications, Dr. Kerr founded and practiced oncology at Southwest Regional Cancer Center.
Dr. Kerr is a Magna Cum Laude graduate of Elizabethtown College, and an AA graduate from University of Pittsburgh School of Medicine. After completing an internship and residency in Internal Medicine at the University of Pittsburgh Hospitals, he completed a fellowship at the University of Minnesota. Dr. Kerr has held faculty positions at the University of Minnesota and the University of Texas- San Antonio.
A. Lelo Diaz
Lelo Diaz has been working in clinical trials for over seven years. Mr. Diaz attended the University of Texas Medical School in Galveston for three years. It was during that time that he was introduced into the industry. While on leave from school he worked as a Research Coordinator. This led to various roles in Clinical Operations within CROs. Mr. Diaz then opened Redstone Research and has continued to work in support of Sponsor IND applications.
Prior to clinical research, Mr. Diaz conducted preclinical research through the Biomedical Research Training Program at the University of Texas at Austin. Though focused on Oncology, Mr. Diaz has successfully driven a variety of trials to completion. Highlights include writing a research protocol and securing funding for a trial conducted in eight different countries. Additionally, he has attended FDA CDER workshops focused on the requirements and compliance of policies for marketing drug products.
Mr. Diaz has a bachelor of science in Biology from Southern Methodist University. He is a member of the Drug Information Association, the Association of Clinical Research Professionals, BioAustin, Associate Member of the American Society of Clinical Oncology, and a Board Member for the Environmental Healthcare Foundation.
Mark Parham, BA, began his Clinical Research career in 1994 as a Study Coordinator in the Renal Department of Emory University, Atlanta, GA. He had previously spent seven years as a Dialysis Technician/Clinic Assistant. While at Emory, he ran multiple Investigator Initiated and Industry Renal Studies. In addition to study coordinator duties, Mark also conducted research training for Renal Fellows at Emory University.
In 1999, Mark was recruited to Quintiles, Inc. as a Clinical Research Associate where his projects included IBC, Cardiovascular and Oncology studies. Mark became an independent consultant in 2002 where his focus was in oncology studies. Projects included Pancreatic, Lung, Colorectal, Breast, Head & Neck, Ovarian, Diffuse Large B-cell Lymphoma, Malignant Ascites and Melanoma Cancer.
In 2008, Mark was recruited to a local Atlanta Pharmaceutical Company as a Contract, Clinical Project Manager until the company relocated out of state. During this time, Mark was able to transition from diverse field monitoring to internal sponsor management. The experience has given him an industry advantage of having worked on both the sponsor and contractor side.
Mark now continues to share his affinity for clinical research as a monitor, and contributes to each project with a diverse perspective while looking forward to new challenges and opportunities.